TrialJournal for immunotherapy of cancer2026

Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trial.

Andrew S Brohl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.